Will we unlock the benefit of Metformin for patients with Lung Cancer? Lessons from current evidence and New Hypotheses
P Barrios-Bernal, ZL Zatarain-Barrón… - Pharmaceuticals, 2022 - mdpi.com
Metformin has been under basic and clinical study as an oncological repurposing
pharmacological agent for several years, stemming from observational studies which …
pharmacological agent for several years, stemming from observational studies which …
Prevalence of oncogenic driver mutations in Hispanics/Latin patients with lung cancer. A systematic review and meta-analysis
Introduction The frequency of actionable mutations varies between races, and
Hispanic/Latino (H/L) people are a population with different proportions of ancestry. Our …
Hispanic/Latino (H/L) people are a population with different proportions of ancestry. Our …
Global Equity in Clinical Trials: An ASCO Policy Statement
SA Al Sukhun, V Vanderpuye, C Taylor… - JCO Global …, 2024 - ascopubs.org
ASCO is a global professional society representing more than 50,000 physicians, other
health care professionals, and advocates in over 100 countries specializing in cancer …
health care professionals, and advocates in over 100 countries specializing in cancer …
Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial
Background Patients with non-small cell lung cancer (NSCLC) experience a considerable
disease burden, evident in symptomatic and psychological spheres. Advanced cancer …
disease burden, evident in symptomatic and psychological spheres. Advanced cancer …
Survival outcomes of metastatic non-small cell lung cancer patients with limited access to immunotherapy and targeted therapy in a cancer center of a low-and middle …
DF Ballén, CA Carvajal-Fierro, R Beltrán… - Cancer …, 2023 - journals.sagepub.com
Objective To describe the survival outcomes of metastatic non-small cell lung cancer
patients with limited access to immunotherapy and targeted therapy in a cancer reference …
patients with limited access to immunotherapy and targeted therapy in a cancer reference …
Lung Cancer Clinical Trials in Latin America in the Era of Cooperative Groups: A 20-Year Analysis
T Knapp, J Nygaard, J Cassinat, F Galvez… - JCO Global …, 2024 - ascopubs.org
PURPOSE The aim of this study is to characterize lung cancer treatment clinical trials in
Latin America before (January 2001-December 2011) and after (January 2012-December …
Latin America before (January 2001-December 2011) and after (January 2012-December …
A reduced dosing strategy can work for Alectinib in ALK rearranged non small cell lung cancer
DB Sacdalan, JA Lucero - Cancer treatment and research …, 2022 - pubmed.ncbi.nlm.nih.gov
A reduced dosing strategy can work for Alectinib in ALK rearranged non small cell lung cancer
A reduced dosing strategy can work for Alectinib in ALK rearranged non small cell lung cancer …
A reduced dosing strategy can work for Alectinib in ALK rearranged non small cell lung cancer …